1388 related articles for article (PubMed ID: 19217513)
1. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
2. LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Phillips W; Schaefer S
Prev Cardiol; 2010; 13(2):69-71. PubMed ID: 20377808
[TBL] [Abstract][Full Text] [Related]
3. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
4. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
6. Drugs for lipids.
Treat Guidel Med Lett; 2005 Mar; 3(31):15-22. PubMed ID: 15726011
[No Abstract] [Full Text] [Related]
7. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
8. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
9. Statin and ezetimibe combination therapy in cardiovascular disease.
Dembowski E; Davidson MH
Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
[TBL] [Abstract][Full Text] [Related]
10. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
11. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
12. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
Meyers CD; Moon YS; Ghanem H; Wong ND
Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
[TBL] [Abstract][Full Text] [Related]
13. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of ezetimibe.
Cheng AY; Leiter LA
Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
[TBL] [Abstract][Full Text] [Related]
15. Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
Guyton JR
Curr Opin Lipidol; 2010 Aug; 21(4):372-7. PubMed ID: 20625257
[TBL] [Abstract][Full Text] [Related]
16. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
17. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
Jones PH
Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
[TBL] [Abstract][Full Text] [Related]
18. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
Kastelein JJ; Sankatsing RR
Int J Clin Pract; 2005 Dec; 59(12):1464-71. PubMed ID: 16351680
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe: a novel option for lowering cholesterol.
Davidson MH
Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.
Chuang P; Langone AJ
Am J Ther; 2007; 14(5):438-41. PubMed ID: 17890931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
